featured
Efficacy and Safety of the KRAS G12C Inhibitor IBI351 in Patients With Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
J Thorac Oncol 2024 Aug 09;[EPub Ahead of Print], Q Zhou, X Meng, L Sun, D Huang, N Yang, Y Yu, M Zhao, W Zhuang, R Guo, Y Hu, Y Pan, J Shan, M Sun, Y Yuan, Y Fan, J Huang, L Liu, Q Chu, X Wang, C Xu, J Lin, J Huang, M Huang, J Sun, S Zhang, H Zhou, YL WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.